Sidney Kimmel Cancer Center & Tennessee Institute Collaborate on Drug Development
The Sidney Kimmel Cancer Center and the Sarah Cannon Research Institute in Nashville, Tennessee, are collaborating on clinical research in early-phase drug-development programs and investigator-initiated trials.
The organizations will combine expertise in drug development and research support services, which will expand the menu of clinical trials to patients across the Delaware Valley and beyond. Additionally, Sarah Cannon will provide SKCC-designed clinical trials in sites within their national network.
“By combining the strengths of SKCC and Sarah Cannon’s robust cancer programs, we are bringing together experts who share a mission to advance cancer research so that patients will have greater access to the latest treatment options that focus on personalized care,” says Karen E. Knudsen, PhD, director of the NCI-designated Sidney Kimmel Cancer Center – Jefferson Health. “We are excited to form a strategic partnership that will accelerate drug development both nationally and globally, with the goal of impacting a larger population of patients seeking new therapies.”
In addition to the collaboration in clinical research, SKCC and Sarah Cannon will work together to advance blood cancer care through Sarah Cannon’s Blood Cancer Network.